The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Industry at a Glance
Industry Ranking
11 / 207
Overall Ranking
87 / 4723
Industry
Healthcare Equipment & Supplies
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
24.875
Target Price
+48.68%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.18% year-on-year.
Undervalued
The company’s latest PE is -168.71, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 41.91M shares, decreasing 5.32% quarter-over-quarter.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.